Our Pricing

Clinical Trial Weight Loss Results by Wegovy Dose

Published on: June 03, 2026

Understanding wegovy weight loss results clinical trial data helps UK patients set realistic expectations before starting treatment. Wegovy (semaglutide 2.4mg) demonstrated average weight reductions of 15-17% over 68 weeks in the landmark STEP trials, with results varying by dose escalation and patient adherence [1]. At Cured Pharmacy, our UK prescribers assess your suitability for Wegovy and guide you through the dose titration schedule based on this clinical evidence.

STEP Trial Results: What the Clinical Data Shows

The STEP (Semaglutide Treatment Effect in People with obesity) programme comprised five major clinical trials evaluating Wegovy's efficacy in over 4,500 participants [1]. In STEP 1, the largest trial, participants receiving semaglutide 2.4mg achieved an average body weight reduction of 14.9% compared to 2.4% with placebo over 68 weeks [1]. Notably, 86.4% of participants on the full maintenance dose lost at least 5% of their baseline weight, whilst 69.1% achieved at least 10% reduction [1].

STEP 2 specifically evaluated patients with type 2 diabetes, demonstrating an average 9.6% weight reduction alongside improved glycaemic control [2]. This trial confirmed that semaglutide's dual benefits extend beyond weight management, making it particularly valuable for patients with metabolic comorbidities. The consistency of results across diverse patient populations reinforced the MHRA's decision to license Wegovy for chronic weight management in the UK.

What distinguishes these trials is the rigorous methodology: participants received structured lifestyle intervention alongside medication, reflecting real-world clinical practice. All prescription weight loss treatments, including Wegovy, work most effectively when combined with dietary modification and increased physical activity, as our UK prescribers explain during your clinical assessment.

Wegovy Dose Escalation Schedule and Weight Loss Progression

Wegovy follows a carefully designed dose titration protocol to minimise gastrointestinal side effects whilst building therapeutic efficacy [3]. The standard UK dosing schedule begins at 0.25mg weekly for four weeks, then increases monthly through 0.5mg, 1.0mg, and 1.7mg before reaching the maintenance dose of 2.4mg at week 17.

Clinical trial data reveals that weight loss accelerates as patients progress through higher doses. In STEP 1, participants lost an average 5.9% body weight by week 20 (during dose escalation), with the majority of weight reduction occurring between weeks 20 and 68 on the 2.4mg maintenance dose [1]. This pattern underscores why adherence to the full titration schedule matters—discontinuing treatment prematurely reduces overall efficacy.

Your UK prescriber at Cured Pharmacy will monitor your response at each dose level and may adjust the escalation timeline if you experience persistent side effects. Some patients require an additional month at intermediate doses before progressing, which is a clinically appropriate modification supported by prescribing guidance.

Typical Weight Loss Timeline by Dose

During the 0.25mg and 0.5mg initiation phase (weeks 1-8), most patients experience modest weight reduction of 2-4% as the medication begins suppressing appetite [3]. The 1.0mg dose (weeks 9-12) typically produces more noticeable changes, with cumulative loss reaching 6-8% by week 16. Maximum efficacy occurs on the 2.4mg maintenance dose, where clinical trials showed continued weight reduction through 68 weeks, with some participants achieving up to 20% total body weight loss [1].

Factors Influencing Individual Wegovy Weight Loss Results

Whilst clinical trials provide average outcomes, individual results vary based on several factors. Baseline BMI significantly influences percentage weight loss—participants with higher starting weights in STEP trials demonstrated greater absolute weight reduction but similar percentage decreases compared to those with lower BMIs [1]. Age, sex, and metabolic health also affect response, with some evidence suggesting younger participants and those without type 2 diabetes achieve slightly higher reductions.

Adherence to both medication and lifestyle modification profoundly impacts outcomes. STEP trial participants received regular dietary counselling and were encouraged to reduce caloric intake by 500 kcal daily whilst increasing physical activity [1]. Real-world studies examining patients without structured support show attenuated results, reinforcing that Wegovy is not a standalone solution but rather one component of comprehensive weight management.

Genetic factors affecting GLP-1 receptor sensitivity may explain why approximately 10-15% of patients are non-responders, achieving less than 5% weight reduction despite full adherence [4]. Your UK prescriber will review your progress at regular intervals and may recommend alternative treatments if Wegovy does not produce adequate response after six months at the maintenance dose.

Optimising Your Results on Wegovy

To maximise weight loss on Wegovy, UK clinical guidance recommends maintaining a balanced, reduced-calorie diet rich in protein and fibre to complement semaglutide's appetite-suppressing effects. Regular physical activity—aiming for 150 minutes of moderate-intensity exercise weekly—helps preserve lean muscle mass during weight reduction. Staying well-hydrated and eating smaller, more frequent meals can also minimise the gastrointestinal side effects that occasionally limit dose escalation.

Wegovy vs Other Weight Loss Treatments: Comparative Clinical Data

Direct comparison trials help contextualise Wegovy's efficacy relative to other licensed treatments. In the STEP 8 trial, semaglutide 2.4mg was compared head-to-head with liraglutide 3.0mg (marketed as Saxenda in the UK) [5]. Participants on Wegovy achieved 15.8% average weight reduction compared to 6.4% with Saxenda over 68 weeks—a statistically significant difference demonstrating semaglutide's superior efficacy [5].

Tirzepatide, a dual GIP/GLP-1 receptor agonist not yet widely available in UK pharmacies for weight management, showed even greater reductions in the SURMOUNT trials, with average losses of 20.9% at the highest dose [6]. However, Wegovy remains the most established and accessible GLP-1 treatment for weight management in the UK, with extensive real-world safety data and NICE guidance supporting its use in appropriate patients.

Oral treatments like Orlistat (Xenical) and Mysimba produce more modest results—typically 5-10% weight reduction—but may suit patients who prefer non-injectable options or have contraindications to GLP-1 therapies. Your UK prescriber will discuss all licensed alternatives during your consultation at Cured Pharmacy, ensuring you receive the most appropriate treatment based on your medical history and preferences.

Long-Term Weight Maintenance After Wegovy Treatment

The STEP 4 trial specifically examined weight maintenance by randomising participants who had achieved weight loss on semaglutide 2.4mg to either continue treatment or switch to placebo [7]. Those continuing Wegovy maintained their weight loss and lost an additional 7.9% over 48 weeks, whilst the placebo group regained 6.9% of their body weight [7]. This data demonstrates that Wegovy is intended as a long-term treatment rather than a short course.

Discontinuation of semaglutide typically results in gradual weight regain as appetite-regulating effects diminish. UK prescribing guidance therefore recommends ongoing treatment for chronic weight management, with periodic reviews to assess continued benefit and tolerability. Some patients may eventually transition to lower maintenance doses or explore supervised discontinuation once they have established sustainable lifestyle changes.

At Cured Pharmacy, our UK clinical team provides ongoing support throughout your weight management journey, with regular prescription reviews to monitor progress and adjust treatment as needed. All consultations remain free, and you'll receive transparent pricing before each prescription is issued.

What Happens If You Stop Taking Wegovy

Clinical evidence shows that most patients regain approximately two-thirds of lost weight within one year of discontinuing semaglutide if lifestyle modifications are not maintained [7]. However, the metabolic improvements and healthier habits established during treatment can provide lasting benefits. If you need to stop Wegovy due to side effects or other reasons, your UK prescriber will discuss strategies to minimise weight regain and may recommend alternative treatments or structured behavioural support.

Starting Wegovy Treatment at Cured Pharmacy

Beginning your Wegovy journey at Cured Pharmacy starts with a free online clinical assessment that takes under three minutes to complete. Our UK-registered prescribers review your medical history, current medications, and weight management goals to determine whether Wegovy is clinically appropriate for you. All prescription treatments require this assessment, ensuring patient safety and compliance with MHRA regulations.

If approved, your first prescription will begin with the 0.25mg starter dose, with clear instructions for dose escalation over subsequent months. We supply genuine UK-licensed Wegovy pens in discreet packaging, delivered directly to your address. Pricing is transparent and shown upfront—Wegovy is available from £79.00 per prescription, with no hidden consultation fees or membership charges.

Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all clinical services to ensure the highest standards of pharmaceutical care. You can contact our team on (+44) 116 4646009 with any questions about your treatment, and we'll arrange follow-up consultations as needed to monitor your progress and adjust your prescription accordingly.

Why Choose Cured Pharmacy for Wegovy

Cured Pharmacy is a fully registered UK online pharmacy (GPhC Registration Number 9012511) offering the lowest prices guaranteed on genuine UK-licensed medicines. Unlike some providers, we show pricing before your consultation, ensuring complete transparency. Every prescription is reviewed by qualified UK prescribers, and we never compromise on clinical safety to expedite service. With 100% discreet packaging and reliable delivery, we make accessing clinically proven weight loss treatments straightforward and confidential.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
3. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Retrieved from https://www.medicines.org.uk/emc/product/13799/smpc [accessed 13 August 2026]
4. Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021). The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism, 23(3), 754–762. https://doi.org/10.1111/dom.14280 [accessed 13 August 2026]
5. Rubino, D. M., Greenway, F. L., Khalid, U., et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619 [accessed 13 August 2026]
6. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
7. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and clinical trial data represents average outcomes under controlled conditions with structured lifestyle intervention.